The AACR Annual Meeting 2022 abstract categories, along with their related subcategories and subclassifications, are listed below. When you use the Abstract Submission System, these options will be available for your selection. Please choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the AACR Annual Meeting 2022. Please note that these abstract categories may or may not be used as AACR Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification. The regular abstract submission deadline is November 18, 2021 (11:59 p.m. ET) and the late-breaking and clinical trials abstract submission deadline is January 10, 2022 (11:59 p.m. ET).

The AACR is committed to raising awareness about the enormous public health challenge of cancer health disparities and racial inequities. We encourage you to view the relevant abstract subcategories and subclassifications in the listing below. Also, the submission category, COVID-19 and Cancer, provides an opportunity to submit novel work in this timely and critically important area.
ABSTRACT CATEGORIES (cont’d)

**MCB** Molecular/Cellular Biology and Genetics

**MCB01** Cell Growth Signaling Pathways
- Cell signaling
- Cell-cell interactions
- Growth factors
- GTPases, their regulators, and effectors
- Kinases and phosphatases
- Receptors
- Tumor-stromal cell interactions
- Ubiquitin and ubiquitin-like proteins

**MCB02** Cell Death
- Apoptosis
- Autophagy
- Bcl-2 family proteins
- Caspases
- Effectors of apoptosis
- Inhibitor of apoptosis (IAP) family proteins
- Necrosis and necroptosis
- Transcriptional control of apoptosis

**MCB03** Oncogenes and Tumor Suppressor Genes
- Cytoplasmic signal transducers
- Genotype/phenotype correlations
- Nuclear oncoproteins and tumor suppressor genes
- Oncogene growth factors and their receptors
- Tumor suppressor genes

**MCB04** Gene Regulation and Transcription Factors
- Chromatin structure and function
- Gene expression
- Mechanisms of transcription
- Oncogenic transcription factors
- Posttranscriptional and translational control
- Promoters and enhancers of transcription
- Protein-protein interactions in transcription factor function
- Regulation of transcription factor function
- Transcriptional control of cell differentiation

**MCB05** Epigenetics and Epigenomics
- Chromatin structure and function
- DNA methylation
- Epigenetic changes as molecular markers of cancer
- Epigenomics
- Gene silencing
- Histone modification

**MCB06** Cell Cycle
- CDKs and CDK inhibitors
- Cell cycle checkpoints
- Control of cell cycle progression
- Telomeres and telomerase

**MCB07** DNA Damage and Repair
- Chromosomal structural alterations/translocations
- Genomic instability
- Homologous recombination
- Mechanisms of genomic alterations
- Radiation-induced DNA damage

**MCB08** Metabolism and Cancer
- Metabolic pathways
- Metabolomics
- Mitochondrial function
- Signaling pathways that regulate metabolism

**MCB09** Genomics
- Functional genomics
- Genomic profiling of tumors
- High-throughput sequencing
- Large-scale approaches to cancer gene discovery
- Microarrays

**MCB10** microRNAs and Other Noncoding RNAs
- Epigenetic control of miRNA expression
- miRNA profiling in cancer
- miRNA regulation of cancer biology
- miRNA-based diagnostics
- miRNA-based Therapeutics
- miRNAs as tumor suppressors/oncogenes
- Noncoding RNAs

**MCB11** Cellular Stress Responses
- Hypoxia
- Oxidative stress
- Premature cellular aging
- Senescence
- Unfolded protein response

**BCS** Bioinformatics, Convergence Science, and Systems Biology

**BCS01** Bioinformatics and Computational Biology
- Application of bioinformatics to cancer biology
- Database resources
- Molecular modeling
- New algorithms
- New software tools for data analysis
- Sequence analysis
- Statistical methods

**BCS02** Convergence Science and Systems Biology
- Artificial intelligence and machine/deep learning
- Digital pathology and artificial intelligence
- Integrative cancer science
- Mathematical modeling
- Network biology
- Physical sciences in oncology
- Systems engineering

**TB** Tumor Biology

**TB01** Nonclinical Models of Cancer
- 3-D and tissue recombinant models
- Developmental phenotypes of cancer genes
- Human-in-mouse models of human cancer
- Model organisms in drug discovery
- Mouse models of human cancer
- Noninvasive imaging in animal models
- Organoids
- Patient-derived xenograft models
- Zebrafish models of cancer
- Other animal and cell models of cancer

**TB02** Stem Cell Biology
- Adult stem cells
- Cancer stem cells
- Developmental pathways in cancer
- Embryonic stem cells
- Stem cell markers
- Stem cells and regenerative medicine in oncology

**TB03** Tumor Adhesion
- Cell adhesion and extracellular matrix
- Cell-cell adhesion
- Drug resistance

**TB04** Metastasis
- Actin cytoskeleton
- Biomarkers of metastasis
- Epithelial/mesenchymal transition (EMT and MET)
- Expression profiling of tumor progression and metastasis
- Genes that regulate migration and invasion
- Imaging of tumor progression and metastasis
- Invasion and migration
- Metastasis suppressor genes
- Metastasis-promoting genes
- Premetastatic niche
- Therapeutic metastasis prevention

**TB05** Angiogenesis
- Angiogenesis and angiogenesis inhibitors
- Host-tumor interactions
- Molecular mechanisms of angiogenesis
- Novel pro- and antiangiogenic factors
- Tumor microcirculation and the microenvironment

**TB06** Tumor Microenvironment
- Chemokines in the microenvironment
- Drug targets in the microenvironment
- Extracellular matrix and integrins
- Gene expression in the microenvironment
- Immune cells in the tumor microenvironment
- Inflammatory cells as regulators of tumor growth
- Microbiome
- Organ-specific microenvironments
- Proteases and inhibitors in the microenvironment
- Tumor dormancy
- Tumor/stromal interactions
- Tumor-immune system interactions

**TB07** In Vivo Imaging
- Advanced nanotechnology and imaging technology
- Imaging in animal models
- Imaging of molecular and cellular events in the tumor microenvironment
- Imaging of molecular and cellular events in tumors and tumor cells
- Imaging the immune response
- Imaging tumor metabolism
- New targets for imaging
## ABSTRACT CATEGORIES (cont'd)

<table>
<thead>
<tr>
<th>ABSTRACT CATEGORIES</th>
<th>ABSTRACT CATEGORIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB08 Pediatric Cancer - Basic Science</td>
<td>CH02 Structural and Chemical Biology</td>
</tr>
<tr>
<td>(See also CL02: Pediatric Cancer - Clinical Investigations; CT04: Phase I, II, or III Clinical Trials in Pediatric Cancer)</td>
<td>Chemical genetics and genomics</td>
</tr>
<tr>
<td>Developmental origins and drivers of pediatric cancer</td>
<td>Nanotechnology in chemical biology</td>
</tr>
<tr>
<td>Pediatric cancer genomics and epigenomics</td>
<td>Small molecule, protein, and nucleic acid interactions</td>
</tr>
<tr>
<td>Pediatric cancer models</td>
<td>Target identification, small molecule probes, and libraries</td>
</tr>
<tr>
<td>Pediatric cancer tumor microenvironment and tumor heterogeneity</td>
<td>X-ray and NMR structures</td>
</tr>
<tr>
<td>Other</td>
<td>Other</td>
</tr>
</tbody>
</table>

| TB09 Radiation Science | CH03 Proteomics and Mass Spectrometry |
| (See also CL07: Radiation Oncology; ET09: Preclinical Radiotherapeutics) | Biological mass spectrometry and systems biology |
| Modulators of radiation response | Proteomics and biomarker discovery |
| Photobiology/photodynamic therapy | Proteomics and signaling networks |
| Radiation dose fractionation | Other |
| Radiation-activated signaling pathways | Other |
| Radiation-induced gene expression | Other |
| Radiation-induced resistance | Other |
| Radiobiology research | Other |
| Radioprotectors and radiosensitizers | Other |

| TB10 Tumor Evolution and Heterogeneity | ET01 Drug Discovery |
| Causes and consequences of tumor heterogeneity | Antibody technologies |
| Clonal evolution | Biochemical modulators of the therapeutic index |
| Complex adaptive systems | Combination chemotherapy |
| Methods to measure tumor evolution and heterogeneity | Differentiation therapy |
| Other | New targets |
| Other | Novel assay technology |
| Other | Novel drug delivery systems |
| Other | Targeting the tumor microenvironment in drug development |
| Other | Other |

| TB11 Carcinogenesis | ET02 Mechanisms of Drug Action |
| Chemical, environmental, and virus-induced carcinogenesis | Cell cycle mechanisms of anticancer drug action |
| Mutagenesis | Cellular responses to anticancer drugs |
| Other | Interactions of new agents with radiation |
| Other | Role of the microenvironment in therapeutic response |
| Other | Other |

| CH Chemistry | ET03 Drug Resistance |
| Drug Discovery, Design, and Delivery | Drug resistance in molecular targeted therapies |
| Basic and applied nanotechnology and therapeutics | Drug transport and metabolism |
| Chemoinformatics, in silico screening, and computational methods | Novel mechanisms |
| Drug delivery | Regulation of gene expression in drug resistance |
| Drug design | Reversal of drug resistance |
| High-throughput screening (assays and libraries) | Other |
| Lead identification | Other |
| Lead optimization | Other |
| Nanotechnology drug delivery | Other |
| Natural products | Other |
| Synthesis, metabolism, and disposition | Other |

| CH01 Drug Discovery, Design, and Delivery | ET04 Molecular Targets |
| (See also TB09: Radiation Oncology; CL07: Radiation Oncology) | Cell death pathways and treatment |
| Modulation of DNA repair | DNA damage response |
| Molecular classification of tumors for diagnostics, prognostics, and therapeutic outcomes | Identification of molecular targets |
| New nonclinical models for targets | Other |

| ET05 Pharmacology, Pharmacogenomics, and Pharmacogenomics | ET06 Small Molecule Therapeutic Agents |
| (See also ET01: Phase I Adult Clinical Trials) | DNA-reactive agents |
| Cellular pharmacology | Epigenetic targets |
| Molecular pharmacology | HDAC and methyltransferase inhibitors |
| Pharmacogenomics | Novel antitumor agents |
| Pharmacokinetics and pharmacodynamics | Novel targets and pathways |
| Preclinical toxicology | PI3K/AKT inhibitors |
| Other | Proteasome inhibitors |
| Other | Topoisomerases |
| Other | Tubulin agents |
| Other | Tyrosine kinase and phosphatase inhibitors |
| Other | Other |

| ET07 Biological Therapeutic Agents | IM Immunology |
| (See also CL06: Immuno-oncology; IM02: Preclinical Immunotherapy) | Adaptive immunity in tumors |
| Antireceptors | Epigenetic regulation of tumor immunity |
| Apoptosis: Therapeutic manipulation | Inflammation and cancer: Metastasis |
| Growth factor receptors and other surface antigens as targets for therapy | Inflammation and cancer: Tumor initiation and progression |
| Oncogenes, tumor suppressor genes, and gene products as targets for therapy | Immune immunity to tumors |
| Protein kinases and phosphatases as targets for therapy | Microbiome, inflammation, and cancer |
| Role of microenvironment in therapeutic response | Novel animal models |
| Other | Oncogenic pathway-mediated regulation of inflammation and tumor immunity |

| IM01 Tumor Immunobiology | ET08 Gene and Vector-Based Therapy |
| Adaptive immunity in tumors | Antisense molecules |
| Epigenetic regulation of tumor immunity | Gene therapy and radiation studies |
| Inflammation and cancer: Metastasis | Immune modulators |
| Inflammation and cancer: Tumor initiation and progression | Vector systems and targeting strategies |
| Immune immunity to tumors | Other |

| IM02 Preclinical Immunotherapy | Other |
| (See also CL06: Immuno-oncology; ET07: Biological Therapeutic Agents) | Adaptive cell therapy |
| Adoptive cell therapy | Combination immunotherapies |
| Combination immunotherapies | Immune checkpoints |
| Immune mechanisms invoked by other therapies including chemotherapy | Immune mechanisms invoked by radiation therapy |
| Immune monitoring/clinical correlates | Immune response to therapies |
| Immune response to therapies | Immunomodulatory agents and interventions |
| Immunomodulatory agents and interventions | Inflammation, immunity, and cancer |
| Inflammation, immunity, and cancer | Modifiers of the tumor microenvironment |
| Therapeutic antibodies, including engineered antibodies | Other |
| Vaccines (oncolytic and prophylactic) | Other |
ABSTRACT CATEGORIES (cont’d)

CT  Clinical Trials
All clinical trials should be submitted by the January 10, 2022 clinical trials abstract deadline.

CT01  Phase I Adult Clinical Trials
(See also CT05: Pharmacology, Pharmacogenetics, and Pharmacogenomics)

CT02  Phase II Adult Clinical Trials

CT03  Phase III Adult Clinical Trials

CT04  Phase I, II, or III Clinical Trials in Pediatric Cancer
(See also CT02: Pediatric Cancer – Clinical Investigations; TB08: Pediatric Cancer – Basic Science)

CT05  Phase I, II, or III Clinical Trials in the Elderly

CT06  Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations

CT07  COVID-19, Cancer, and Clinical Trials
(See also COVID01: COVID-19 and Cancer)

Phase I
Phase II
Phase III
Phase IV, observational, and expanded access
Clinical trials in progress

CT08  Clinical Trials in Progress
Phase I clinical trials in progress
Phase II clinical trials in progress
Phase III clinical trials in progress

CL  Clinical Research
[not including clinical trials; see also the Clinical Trials (CT) categories]

CL01  Translational Research – Molecular Biology in Clinical Oncology
(See also: TB07: In Vivo Imaging)
Clinical imaging
Cytogenetics and clinical molecular genetics
Epigenetic therapy
Functional and molecular imaging
Laboratory correlates for targeted agents
Molecular classification of tumors
Radiomics
Tumor staging: Correlation of clinical and molecular markers
Other

CL02  Pediatric Cancer – Clinical Investigations
(See also CT04: Phase I, II, or III Clinical Trials in Pediatric Cancer; TB08: Pediatric Cancer – Basic Science)
Adolescent and young adult oncology
Childhood cancer drug development
Immunotherapeutic approaches to pediatric cancer
Pediatric cancer predisposition and surveillance
Survivability, late effects, and second cancers
Therapeutic dosing, resistance, and combination therapy approaches in pediatric oncology
Translational pediatric cancer research
Other

CL03  Clinical Research in the Elderly
Aging, immunity, and cancer
Other

CL04  Clinical Research in Racial and Ethnic Minorities and Other Underserved Populations
Biobanking/biops specimen collection
Clinical trial design
Community-engaged research/community-based participatory research
Community outreach and patient accrual
Impact of COVID-19 on patient accrual
Other

CL05  Biostatistics in Clinical Trials
Design and analysis of clinical trials
New study designs: Theory, methodology, and modeling
Statistical modeling for cancer studies
Other

CL06  Immuno-oncology
(See also ET07: Biological Therapeutic Agents; IM02: Preclinical Immunotherapy)
Adaptive cell therapy
Combination immunotherapies
Immune checkpoints
Immune mechanisms invoked by other therapies including chemotherapy
Immune mechanisms invoked by radiation therapy
Immune monitoring/correlates
Immune response to therapies
Immunomodulatory agents and interventions
Inflammation, immunity, and cancer
Modifiers of the tumor microenvironment
Therapeutic antibodies, including engineered antibodies
Vaccines (oncolytic and prophylactic)
Other

CL07  Radiation Oncology
(See also TB09: Radiation Science; ET09: Preclinical Radiotherapeutics)
Clinical radiotherapeutic studies
Interventional radiology
Modification of radiosensitivity
Radiation-immunotherapy and other radiotherapeutic combinations
Radiation-induced late effects/second cancers
Radiation-induced resistance
Other

CL08  Surgical Oncology (including Prophylactic Surgery)
Surgical oncology

CL09  Clinical Endocrinology
(See also EN01: Molecular, Preclinical, and Clinical Endocrinology)
Endocrine-related cancers
Hormone receptors and diagnosis/prognosis
Hormone signaling and inhibitors
Hormone synthesis, metabolism, and inhibitors
Neuroendocrine and other endocrine factors
Nuclear receptors: Structure and function
Preclinical studies of endocrine-related cancers
Receptors and signal transduction
Steroid hormone receptors
Other

CL10  Survivorship Research and Supportive Care
Biology of cell and tissue damage
Cardio-oncology
Comparative effectiveness research and cost-effective studies
Late effects of cancer and its treatment, including second cancers
Psycho-oncology
Supportive care, palliation, and pain management
Translational survivorship research
Other

CL11  Biomarkers
Biomarkers predictive of therapeutic benefit
Diagnostic biomarkers
Early detection biomarkers
Liquid biopsies: Circulating DNA
Liquid biopsies: Circulating tumor cells
Metastasis biomarkers
Prognostic biomarkers
Spatial proteomics and transcriptomics
Other

CL12  Clinical Outcomes Research
Clinical outcomes research

CL13  Real-World Data (RWD) and Real-World Evidence (RWE)
Analyses using clinico-genomic databases
Clinical informatics and data science
Retrospective clinical analyses
Other

CL14  Precision Oncology
Combination therapy
Molecular targeted therapy
Other

EN  Endocrinology

EN01  Molecular, Preclinical, and Clinical Endocrinology
(See also CL09: Clinical Endocrinology)
Endocrine-related cancers
Growth factors, receptors, and signal transduction
Hormone receptors and diagnosis/prognosis
Hormone signaling and inhibitors
Hormone synthesis, metabolism, and inhibitors
Neuroendocrine and other endocrine factors
Nuclear receptors: Structure and function
Preclinical studies of endocrine-related cancers
Receptors and signal transduction
Steroid hormone receptors
Other

Submission Deadline: November 18, 2021 (11:59 p.m. ET)
Late-Breaking and Clinical Trials Abstract Submission Deadline: January 10, 2022 (11:59 p.m. ET)
ABSTRACT CATEGORIES (cont’d)

PS  Population Sciences

PS01  Population Sciences
Aging as a risk factor
Biomarkers of endogenous or exogenous exposures, early detection, and biologic effects
Biomarkers of prognosis
Cancer health disparities research
Descriptive epidemiology, covering cancer incidence, mortality, clusters, and trends
Diet, alcohol, tobacco use, and other lifestyle risk factors
Environmental and occupational risk factors
Familial and hereditary cancers
Functional studies of genetic variants
Gene-gene and gene-environment interactions
Genome-wide association studies (GWAS)/post-GWAS
Health services and comparative effectiveness research
Infection and immune factors
Next-generation sequencing in epidemiology studies (whole genome, exome, targeted, or fine-mapping)
Pathway and candidate gene studies of risk or prognosis
Pharmacoepidemiology
Preneoplastic and tumor markers
Primary and secondary intervention studies
Risk prediction models for incidence, prognosis, and/or mortality
Screening and early detection
Statistical and epidemiological methodology
Survivorship research
Other

PR  Prevention, Early Detection, and Interception

PR01  Preclinical Prevention, Early Detection, and Interception
Animal models in prevention
Biological and biochemical mechanisms in prevention
Biomarkers and intervention studies
Cellular models
Chemoprevention studies
Diet, nutrition, and cancer
Molecular markers in prevention research
New agent development
Screening and early detection
Other

PR02  Clinical Prevention, Early Detection, and Interception
Application of molecular pathology in clinical prevention
Biomarkers and intervention studies
Cancer health disparities research
Cancer surveillance and screening studies
Chromoprevention clinical trials
Genetic markers as surrogate endpoints in prevention trials
Genomics and proteomics in cancer risk and response assessment
Infections and virus-related cancers
Microbiome and prevention
Prevention and treatment of premalignant lesions (intraepithelial neoplasia)
Prevention of second cancers
Recruitment of racial and ethnic minorities and other underserved populations in clinical prevention trials
Screening and early detection
Other

PR03  Implementation Science
Behavioral science and prevention
Cancer communication and decision-making
Cancer health disparities research
Genetic testing and counseling
Health policy and outcomes
Obesity, diet, physical activity, and energy balance
Quality of life/late effects/survivorship
Other

COVID  COVID-19 and Cancer

COVID01 COVID-19 and Cancer
Cancer drug repurposing to treat COVID-19
Cancer prevention and early detection during the COVID-19 pandemic
Clinical trials (See also CT07: COVID-19, Cancer, and Clinical Trials (Phase I–Phase IV and Trials in Progress))
Continuity of cancer care
COVID-19 vaccine development
COVID-19 vaccines and immune responses among cancer patients
Diagnosis and treatment of COVID-19: Design, development, and validation
Effects of cancer immunotherapies on patients with COVID-19 (with or without cancer)
Effects of COVID-19 on cancer survivorship
Epidemiology and registries of COVID-19 and cancer (including biorepositories)
Health inequities and disparities during the COVID-19 pandemic
Intersection of the biology of SARS-CoV-2 and cancer
Risk factors and comorbidities resulting in adverse outcomes for cancer patients with COVID-19
Science and public policy
Other

RSP  Regulatory Science and Policy

RSP01  Regulatory Science and Policy
Biosimilars and generics
Clinical trial design and accrual
Combination therapies and codevelopment of investigational agents and diagnostics
Data science and informatics
Novel endpoints and biomarkers
Real-world evidence and retrospective analyses
Tobacco and e-cigarette regulation
Other

SHP  Science and Health Policy

SHP01  Science and Health Policy
Cancer health disparities
Cancer survivorship
Comparative effectiveness research
Implementation science
Patient advocacy and engagement
Value and cost issues in cancer care
Other